POPULARITY
16 episodes with community oncology
3 episodes with community oncology
2 episodes with community oncology
2 episodes with community oncology
2 episodes with community oncology
2 episodes with community oncology
Bispecific antibodies (BsAbs) have transformative potential in cancer treatment and can be successfully integrated into community oncology practices. To support this integration, ACCC is committed to providing educational initiatives and support for cancer care teams to optimize care coordination. In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices. Dr. Koff sheds light on the opportunities for future partnerships with academic centers and community oncology sites to ensure there is proper infrastructure and training to safely administer bispecific antibodies. “We're only at the beginning here; I think that as new bispecific agents are developed, there may be other indications in which they can be used, so it will be a broader population of patients who may end up being eligible to receive these drugs.” -Jean Louise Koff Jean Louise Koff, MD, MSc Associate Professor, Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta, GA This podcast was developed in connection with APSHO and LRF and made possible with support by Genentech and Johnson & Johnson. Resources: ASCO Use of BsAbs in Community AJMC Obstacles to Optimal Transition Between Academic and Community Centers
In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—continue their exploration of oncology practice economics, focusing on practices' operational realities.
In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider. and oncology strategist—explore the current state of oncology practice economics.
View Activity Information…
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer. Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including: • The importance of surgical staging and primary debulking surgery • The role of genetic testing, including BRCA and NGS, in treatment planning • Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumab • Insights into PARP inhibitors and their application in BRCA-positive and wild-type patients • Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd). Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies. Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology! Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of gynecologic oncology, focusing specifically on endometrial cancer. Hosted by Drs. Rohit and Rahul Gosain, this episode features Dr. Shannon Westin, a Professor of Gynecology, Oncology, and Reproductive Medicine at the MD Anderson Cancer Center. In this episode, we explored: • The different histologies of endometrial cancer, including endometrioid, serous, clear cell, and undifferentiated types. • The evolving landscape of molecular classification and its impact on treatment decisions. • The current treatment paradigms for early-stage and advanced endometrial cancer, including the role of surgery, chemotherapy, and immunotherapy. • The significance of NGS (Next-Generation Sequencing) testing in identifying actionable mutations, such as MSI-high tumors and HER2-positive cancers. • The latest advancements in adjuvant therapies and the potential of combining chemotherapy with immunotherapy. Whether you're a healthcare professional or simply interested in the latest developments in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't forget to like, subscribe, and check out our other discussions focusing on ovarian cancer and more! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification. Key topics included: • The importance of molecular testing in AML diagnosis and treatment planning • The role of intensive induction chemotherapy and the classic 7+3 regimen • New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax • Strategies for managing elderly or frail patients who are ineligible for intensive chemotherapy • The significance of measurable residual disease (MRD) in treatment decisions and transplant eligibility • Insights into managing side effects and complications associated with AML treatments Join us for an informative discussion that sheds light on the evolving treatment landscape of AML and the importance of personalized care in oncology. Don't forget to check out our other episodes on hematological malignancies, and we look forward to seeing you at ASH 2024! Subscribe to our channel for more insights and updates in the world of oncology! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Community Oncology Pharmacists - Their Crucial Role and Clinical Impact: Andrea Roman, PharmD, BCOP by i3 Health
As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy. “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD Guest: David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma. Additional Reading/Sources ACCC Oncology Issues Article If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology
In this episode of Targeted Talks, Nini Wu, MD, MBA, chief medical and development officer at Cardinal Health, shares her insights on the ever-changing world of technology in the community oncology setting.
In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang: - CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer - BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations - AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation - Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma
In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz: - CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer - EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization - NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors
In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate: - TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis - MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis - SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML - AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results #ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/
In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover: - APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression - KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis - HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer
In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo: - NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis - MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer - INAVO120 – Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2– Locally Adv/Metastatic Breast Cancer - TROPION-Breast01 – Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2– Breast Cancer
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: - ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p) - SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma - POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study
In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: - PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) - IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM - Bortezomib Dosing - Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM - KarMMA-3 Update - Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis
In discussion with Dr. Eleonora Teplinsky, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Teplinsky: - NSABP B-51 – Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node Negative After Neoadjuvant Chemotherapy - IDEA Update – Five-year Outcomes of the IDEA trial of Endocrine Therapy Without Radiotherapy After Breast-Conserving Surgery for Postmenopausal Patients Aged 50-69 With Genomically-Selected Favorable Stage I Breast Cancer - ICARO - Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated with Axillary Dissection or Nodal Radiation - Keynote-522 Update - Event Free Survival with neoadjuvant and adjuvant pembrolizumab in TNBC
In this episode, you will hear from the research leads for each of our key customer segments about 3 notable quotes they heard from conversations this year with providers, payers, and administrators in the oncology sector.
As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy. “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD Guest: David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma. Additional Reading/Sources If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology
In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff: - Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer - CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus - GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma
In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira: - PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions - MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC - MARIPOSA-2 – Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After Progression on Osimertinib - LIBRETTO-431 – First-line Selpercatinib or Chemo and Pembrolizumab in RET Fusion-Positive Advanced NSCLC
In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton: - Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm - TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer, with better PFS and ORR favoring Dato-DXd - Keynote 522 - Event Free Survival update with neoadjuvant and adjuvant pembrolizumab in TNBC, continue to show benefit
In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: - SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG - with TAR-200 mono therapy achieving 77% overall complete response rate - EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS - PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness
In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss: - Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data - ALINA – resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS - TropionLung 01 – Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel #ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers
Drs Patel, Wright, and Devoe revisit their involvement in the SWOG S1801 trial to highlight available resources that can expand the reach of cancer care in the community oncology setting. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989040). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Malignant Melanoma https://emedicine.medscape.com/article/280245-overview Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma https://www.nejm.org/doi/full/10.1056/NEJMoa2211437 Event-Free Survival https://www.cancer.gov/publications/dictionaries/cancer-terms/def/event-free-survival National Cancer Institute Community Oncology Research Program (NCORP) https://prevention.cancer.gov/major-programs/nci-community-oncology-research-program-ncorp SWOG Cancer Research Network https://www.swog.org/ ECOG-ACRIN Cancer Research Group https://ecog-acrin.org/ NRG Oncology https://www.nrgoncology.org/ Children's Oncology Group https://childrensoncologygroup.org/ Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/article-abstract/2798988 Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II) https://clinicaltrials.gov/study/NCT03860883
In discussion with Dr. Sapna Patel, Associate Professor, Director of the Uveal Melanoma, and Melanoma Fellowship Program Director at the MD Anderson Cancer Center we discuss how to treat Cutaneous Melanoma and important nuances from Community Oncology perspective. - Management of Stage 0/IA melanoma - where management is mainly surgery - Who is the most appropriate candidate for lymph node evaluation - Stage IIB and beyond, discussing choice of observation, radiation or immunotherapy especially given recent promising results - In patients with metastatic disease, how to manage BRAF positive vs. negative patient population
In this episode, we provide highlights on key insights from our 2023 Community Oncology Annual Trend Report, including why it's important for pharma companies to tailor their approach with community oncology groups based on what archetype they fall under.
In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Liu: - FLAURA2 - studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets - CHRYSALIS-2 - post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo - MARS2 - when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma - EVOKE-02 - Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space #WCLC #IASLC #LungCancer #2023 #cancer #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Dr. Supriya Mohile , Dr. William Dale, and Dr. Heidi Klepin discuss the updated guideline on the practical assessment and management of age-associated vulnerabilities in older patients undergoing systemic cancer therapy. They highlight recent evidence that prompted the guideline update, and share the updated evidence-based recommendations from the panel, focusing on geriatric assessment-guided management. Dr. Mohile also reviews what the expert panel recommends should be included within a geriatric assessment, and Dr. Dale highlights the Practical Geriatric Assessment tool, aimed at helping clinicians implement a geriatric assessment. Dr. Klepin comments on the impact for both older adults with cancer and their clinicians, and reviews outstanding questions and challenges in the field. Read the full guideline, "Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the update and review authors' disclosures of potential conflicts of interest disclosures in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.00933. See also the Practical Geriatric Assessment tool and associated videos (How to do a Geriatric Assessment, What to do with the Results of a Geriatric Assessment) mentioned in the podcast episode. Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. William Dale from City of Hope National Medical Center, Dr. Heidi Klepin from Wake Forest Baptist Comprehensive Cancer Center, and Dr. Supriya Mohile from University of Rochester Medical Center—co-chairs on “Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.” Thank you for being here, Dr. Dale, Dr. Klepin, and Dr. Mohile. Dr. William Dale: Nice to see you. Thanks for having us. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensures that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including our guests joining us on this podcast episode today, are available online with the publication of the guideline in the Journal of Clinical Oncology linked in the show notes. Diving into the content of this guideline first, Dr. Dale and Dr. Mohile, can you speak to what prompted an update of this ASCO guideline on the practical assessment and management of age-associated vulnerabilities in older patients undergoing systemic cancer therapy, which was previously published in 2018? Dr. William Dale: Sure. Yes. In 2018, that was the very first guideline for older adults that ASCO had created, and that was based on work that had been done up to that time, focused on chemotherapy toxicities. And to summarize what was put out at that time, the evidence was thought to be strong enough for doing geriatric assessments. And these are specialized assessments across a number of domains, including functional impairments, cognitive losses, social impairments, etc. But to do these kinds of geriatric assessments with validated tools; that a certain selection of these domains to cover everything that was relevant; to conduct non-cancer prognostication so that for decision-making purposes, if someone were to have their cancer cured, what would be their prognosis, and help make decisions about giving chemotherapy and what doses; and then to enact geriatric assessment-guided target interventions was the fourth recommendation. And so that's where we were in 2018. In 2020 at ASCO, there was an oral session that had four randomized controlled trials that enrolled older adults. And in that was kind of the signal that there was more coming. And in 2021, two big trials that are practice-changing were published. One led by Dr. Mohile in Lancet that we call the GAP70+ study, and another one was published in JAMA Oncology. And they essentially showed the same thing, which was that GA-guided interventions could change the primary outcome, which was to reduce chemotherapy toxicity up to 20%, and also to affect a number of other outcomes. That, along with a number of other trials that have since come out and are included in the upcoming guidelines, and made it a high priority to update these guidelines. So that's where we got from there to here. And I think it's worth saying a few words about these new trials, particularly the GAP and GAIN studies. So the GAIN study included patients who were 65 and older who were starting systemic chemotherapy and looked at the likelihood of having chemotherapy toxicity as described and looked at a number of other outcomes. Most importantly, it showed that chemotherapy toxicity could be reduced with these interventions based on the geriatric assessment from about 60% to about 50%. It also showed that the likelihood of completing advanced directives would go up by around 25%. And importantly, there was no impact after all of the use of the geriatric assessments on mortality. So patients were living just as long, but they were having less toxicity and they were having more goal-concordant care. And at almost the same time, the GAP study came out, which I would hand over to Dr. Mohile to describe. Dr. Supriya Mohile: Thank you, Dr. Dale. I agree that it was time for an update, and I'm glad ASCO partnered with us to do this. I'll also just mention that Dr. Dale, Dr. Klepin, and I lead the Cancer and Aging Research Group, and many of the original predictive models that showed that geriatric assessment could help us identify patients at highest risk for toxicity were designed by Cancer and Aging Research Group investigators. And that's what informed the first guideline. I'll mention Dr. Arti Hurria, who unfortunately passed away a few years ago, and she led some of the first large studies that developed these predictive models. We built on that data in both GAP and GAIN studies to show that the geriatric assessment—when you assess and provide management—can reduce chemotherapy toxicity. Like GAIN, GAP70+ implemented a geriatric assessment intervention that both assessed and provided management to older adults. There were some key differences. In GAP70+, the patients had advanced cancer, whereas, in the GAIN study, it was a more generalizable population of patients with both curative intent and advanced cancer. And in the GAP70+ study, we enrolled patients who already had geriatric assessment domain impairments, meaning that these patients were more vulnerable because of those aging-related conditions. We were trying to enroll patients who are traditionally excluded from therapeutic clinical trials. The GAP70+ study was done in oncology offices by Community Oncology practices. So this was what I think was really interesting, in that geriatricians were not involved in implementing the geriatric assessment in this study. Oncologists received the assessment information from their team, and they're the ones that implemented the recommendations. We found in GAP70+ that not only chemotherapy toxicity was reduced, that we were able to reduce the prevalence of falls and reduce the incidence of polypharmacy, which are important geriatric outcomes for older adults. We included patients who were receiving chemotherapy, but also patients who are receiving high-risk targeted agents in GAP70+, which also leads us to believe that these interventions are important for patients who are receiving treatments other than chemotherapy. So we believe these two trials, plus others, really inspired the ASCO guidelines. Brittany Harvey: Absolutely. I appreciate you both for providing that context and background and some of the new evidence that's informed this latest update. So then I'd like to move into some of the updated recommendations of the guideline. So, Dr. Mohile, what is the updated recommendation from the panel regarding the role of geriatric assessment in older adults with cancer? Dr. Supriya Mohile: So the first guideline really focused on the assessment piece, what should be assessed, and why, which we still incorporate in this new guideline. This guideline extends now because of the randomized controlled trials into management. And when we think about geriatric assessment, we think about two pillars of management. One is how geriatric assessment influences cancer decisions, that includes what treatments to provide, what dose to provide. And then the second is how geriatric assessment can influence management recommendations that are supportive care based that address some of the geriatric assessment domain impairments. I'll just give you an example of both. So when we see patients with advanced cancer who have geriatric assessment domain impairments who are presenting for treatment, often the doses of chemotherapy may be overtreatment because those doses were developed in therapeutic clinical trials in younger, more fit patients. And in our geriatrics world, we often think about going slow and starting low, and we may do a first cycle that's dose reduced a touch, to kind of see how the patient does physiologically with that first cycle. There are therapeutic clinical trials like FOCUS2 in patients with metastatic colon cancer that show the benefits of being careful with dosing in the first cycle. So, in GAP70+, the oncologists who received information from the assessment were more likely to reduce the dose of the treatment in the first cycle which led to less toxicity but did not lead to a difference in survival, so do not compromise survival. And I think this is because we don't know the right doses for patients who have significant aging-related impairments. So that's one example of decision-making. As examples for geriatric management recommendations that are supportive care, this can be done in almost like an algorithmic approach. So, if a patient has an impairment on a physical function test, then through the geriatrics literature we know of management recommendations that can improve outcomes like physical therapy, home safety evaluations, balance, training, fall prevention information. And if we implement those supportive care recommendations through that patient who's at risk for falls, we may prevent falls and we were able to show that in addition in GAP70+ as well as other trials showed benefits in some of those outcomes. And so those are the two pieces that I think are newer with this guideline than with the previous guideline. We know more about how those management recommendations can improve outcomes. Brittany Harvey: Understood. Yes. It's helpful to understand those examples of how integrating this geriatric assessment can help improve the management of care for these patients. So then you've mentioned some of the geriatric assessment domain impairments. So, Dr. Mohile, what does the guideline recommend should be included within a geriatric assessment? Dr. Supriya Mohile: This was a really great question for us to rise and think about, as part of this guideline and as a panel, we went back and forth with all of the authors to try to think about what is the most streamlined number of domains that should be assessed? What are the highest priority domains that, if you could only do a few things in a busy oncology clinic, which are the ones that oncologists should have to do because without doing them, they won't have relevant information to inform treatment decisions or to improve the outcomes of their patients? And so when we think about geriatric assessment, there has been literature to show that almost all of the domains we do are important in identifying patients who are at risk of poor outcomes. These include physical function, cognitive function, emotional health, comorbidities, polypharmacy, nutritional status, and social support. That sounds like a lot, but we do many of those assessments sort of naturally in oncology clinics. There are just a few that are not done as standard. For example, it is not standard for oncologists to assess cognition using a validated screening test for cognition. And we know that recognizing patients who may have cognitive impairment is really important in identifying vulnerabilities and providing support systems in place so patients who are receiving treatment can go through treatment safely. Other things, like just doing a formalized nutritional assessment, really bringing in the caregiver, are done not in a standard way. And so what the geriatric assessment allows is for us to assess each of those domains in a standard way. When we're communicating to our colleagues and tumor boards, we can describe vulnerabilities in a standard way. And we're moving now past the eyeball test, which is different for different clinicians, and having more objective ways of describing health status to be able to have a common language across studies and in clinical care. Brittany Harvey: That's helpful to understand moving past the less formal approach to geriatric assessment and making it more standardized. So then, Dr. Dale, this guideline offers a specific tool, the Practical Geriatric Assessment, as an option for clinicians conducting a geriatric assessment. What is this tool and where can clinicians access it? Dr. William Dale: Very good question. Just to set the context a bit, after hearing about all the evidence that we've just described. We did do some work as a task force through ASCO and through some work that Dr. Klepin and her colleague have done to understand now that the guidelines in 2018 had come out, they weren't really being used. So when we asked, about 25% of people would say they were using them very much, even though we saw in these large studies that we did, that those who were using the guidelines were changing their practice significantly in the ways that Dr. Mohile mentioned. And this was among a large group of community oncologists. So we have been breaking down the geriatric assessment into the most concise, most straightforward, and easiest-to-use version of the geriatric assessment, maintaining its validity and maintaining the number of domains. We really tried to make it simple. So the Practical Geriatric Assessment is not the only tool, but it is a tool that accomplishes this practical charge to make it accessible to community oncologists while also being valid. So those domains that Dr. Mohile mentioned physical function, functional status, nutrition, social support, psychological considerations, comorbidities are all in the Practical Geriatric Assessment. But what we've done is boil it down to here's a very specific tool that we think is valid but easily applied. Here are the very specific thresholds that tell you when a deficit has been identified and then gives recommended actions to be taken, whether it's in decision-making or in other interventions like a referral to somebody, perhaps physical therapy, or a cognitive specialist, all of which come from the GAP. So this tool is designed to be very straightforward and practical, but still cover all the relevant domains. And it will be made available through both the ASCO website and through the Cancer and Aging Research Group website so that people can access it easily. Brittany Harvey: That sounds like a real challenge that the ASCO working group took on to create a comprehensive yet practical tool for clinicians to use. We'll also provide some links for people to access this in the show notes of this podcast episode. So then I want to move on. Dr. Klepin, in your view, how will this guideline update impact both clinicians and older adults with cancer? Dr. Heidi Klepin: Yes. Thank you. As was mentioned, for clinicians, the guidelines provide an overview of new evidence and concrete recommendations to address the challenge experienced every day in practice, that of providing personalized care in the context of age-related conditions to maximize benefits and minimize the risk for older adults with cancer. The evidence summary will educate clinicians on key outcomes that can be positively impacted by use of geriatric assessment, including decreasing treatment toxicity, enhancing decision-making, and improving communication and patient-caregiver satisfaction. And this information on outcomes is really critical to informing the use of geriatric assessment in practice. We hope that the evidence-based recommendations with the provision of the practical geriatric assessment and the associated trigger table to guide management strategies will empower clinicians to incorporate geriatric assessment into their workflow by helping them overcome some of those known barriers that Dr. Dale mentioned, such as lack of time and uncertainty about which measures to use and what to do with the information once you have it. So, we anticipate that providing clear recommendations and accompanying readily available materials to support the implementation that clinicians in both community and academic practices will be able to use the geriatric assessment and incorporate it into routine care. For patients, we anticipate that the guideline recommendations would translate into increased use and access to this type of assessment as part of their routine oncology care. So, we hope that our patients will actually be able to access this regardless of whether they're receiving care at a specialized academic center versus a community oncology clinic. So, by doing this, we would extend the proven benefits of geriatric assessment, including lower rates of side effects, experiencing fewer hospitalizations, and improving satisfaction to older adults regardless of where they receive treatment. And we feel like this is critically important, since currently, most older adults receive cancer care in community oncology clinics without access, as was mentioned, to any geriatric specialty care. So, as more older adults have the opportunity to participate in this type of assessment as part of routine care in their oncology clinics, they'll be able to discuss the results of the assessment with their healthcare providers, which can help them make better-informed decisions and engage, I think, more completely in what we would consider patient-centered decision making. And ultimately, we would hope that the guidelines would provide an evidence-based and practical strategy for improving the quality of care received by older adults with cancer. Dr. Dale, would you be interested in commenting a little bit more on the patient perspective informed by our patient partners on the guideline panel? Dr. William Dale: Yeah. Thank you, Dr. Klepin. Very well said. Yeah, our guideline panel, just to fill out the picture of that, included our patient partners, along with a wide diversity of perspectives. We had experts in geriatric oncology, but we had community oncologists who take care of cancer patients. We have people from across the country. We had different backgrounds and different levels of experience. But to focus on the patients for a group that we've worked with for some time called SCOREboard, and they were some of the strongest voices on this. Whenever people said, “Well, do we really need to require this?” The patient partners were insistent that this be included as a requirement as much as possible for what happens. I think one of the most important roles they've played is as advocates for this. If I can, when the community oncologists are having some concerns about how hard this would be or how difficult it might be, the patient partners have been the first to say, we need to find a way to do it and insist that we empower the patients to ask for it. So, one of the hopes for all of these guidelines is also that it get disseminated to patients who can self-advocate as they go forward and have tools that will be made available for them to use in this self-advocacy. Brittany Harvey: Definitely, that self-advocacy is important and the geriatric assessment is critical for optimal care for older adults. So, then we've talked a lot about the new evidence regarding geriatric assessment and also making it easier for clinicians to implement the geriatric assessment, but Dr. Klepin, what are the outstanding questions and challenges regarding geriatric assessment in older adults with cancer? Dr. Heidi Klepin: Thanks. So, while there's strong evidence and clear rationale to incorporate geriatric assessment into routine clinical care, there are outstanding questions and challenges that we have to consider. First and foremost, still remains a challenge of implementation. As mentioned, we hope that the Practical Geriatric Assessment, the detailed recommendations, and the associated educational materials on what to do with the geriatric assessment information will help overcome implementation barriers for many. But we recognize that more work needs to be done to both train providers to facilitate behavior change as well as to tackle clinic and healthcare system barriers to routine use. And along these lines, we also recognize that it's important to educate patients and caregivers about the role of geriatric assessment and its value in order to optimize uptake in community clinics. We want all of our patients to be as enthused and recognize the importance of the geriatric assessment, as our colleagues on the recommendation panel did. Another consideration is the challenge of tailoring use of geriatric assessment to specific disease and treatment settings. And more research is underway testing geriatric assessment and management strategies in varied disease settings, as well as with varied treatment types and intensities. And finally, I would suggest that another challenge is the lack of routine incorporation of geriatric assessment measures into cancer clinical trials. And this will really be necessary to interpret clinical trial data for older adults optimally and to reinforce the value of routine geriatric assessment in clinical care. Brittany Harvey: Absolutely. These are key points for moving forward and looking forward to additional research in this area and maybe future guideline updates down the line. So, I want to thank you all so much for your work on updating this guideline and for your time today. Dr. Dale, Dr. Klepin, and Dr. Mohile. Dr. Heidi Klepin: Thank you for having us. Dr. William Dale: Yeah, thanks for having us here. We're delighted to be talking about this. Dr. Supriya Mohile: Thank you. And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Welcome to Episode 26 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 26 of “The 2 View” – Save time charting & code accurately, dementia, PE in pregnancy, and the PCN shortage. PCN Shortage Ault, A. FDA Drug Shortages. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. FDA issues new rule on drug shortages. Community Oncology, 9(1), 34. U.S. Food & Drug. Published April 26, 2023. Accessed May 9, 2023. https://doi.org/10.1016/j.cmonc.2011.12.003 Bendix, A. Shortage of penicillin limits access to the go-to drug for syphilis. NBC News. Published April 27, 2023. Accessed May 9, 2023. https://www.nbcnews.com/health/health-news/shortage-penicillin-limits-access-go-drug-syphilis-rcna81777 Global shortages of penicillin. Shortages of benzathine penicillin. Global Sexually Transmitted Infections Programme. World Health Organization. Who.int. Accessed May 9, 2023. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/stis/treatment/shortages-of-penicillin Dementia Alzheimer's Disease Fact Sheet. Alzheimer's Disease and Related Dementias: Basics of Alzheimer's Disease and Dementia. National Institute on Aging. Accessed May 9, 2023. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet Home. Alzheimer's Disease and Dementia. Alzheimer's Association. Accessed May 9, 2023. https://www.alz.org/ Silbert, L, Erten-Lyons, D. Memory Loss, Confusion in a 51-Year-Old Fired From Her Job. Medscape. Published March 2, 2023. Accessed May 9, 2023. https://reference.medscape.com/viewarticle/850363 PE in Pregnancy Negaard M. YEARS Algorithm for pulmonary embolism (PE). MDCalc. Accessed May 9, 2023. https://www.mdcalc.com/calc/4067/years-algorithm-for-pulmonary-embolism-pe Stals MAM, Moumneh T, Ainle FN, et al. Noninvasive diagnostic work-up for suspected acute pulmonary embolism during pregnancy: a systematic review and meta-analysis of individual patient data. J Thromb Haemost. 2023;21(3):606-615. NIH: National Library of Medicine: National Center for Biotechnology Information. PubMed. Published December 22, 2022. Accessed May 9, 2023. https://pubmed.ncbi.nlm.nih.gov/36696189/ Thromboembolism in Pregnancy. ACOG: The American College of Obstetricians and Gynecologists. Acog.org. Practice Bulletin, Number 196. Published July 2018. Accessed May 9, 2023. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/07/thromboembolism-in-pregnancy Charting & Coding 2023 Emergency Department Evaluation and Management Guidelines. ACEP: American College of Emergency Physicians. Acep.org. Last Updated: October 2022. Accessed May 9, 2023. https://www.acep.org/administration/reimbursement/reimbursement-faqs/2023-ed-em-guidelines-faqs American Medical Association. 2023 Emergency Medicine Coding Guide. MDCalc. Accessed May 9, 2023. https://www.mdcalc.com/calc/10454/2023-emergency-medicine-coding-guide CPT Evaluation and Management (E/M) Code and Guideline Changes. AMA: American Medical Association. Ama-assn.org. Accessed May 9, 2023. https://www.ama-assn.org/system/files/2023-e-m-descriptors-guidelines.pdf ICD-10-CM Coding for Social Determinants of Health. AHA: American Hospital Association – Advancing Health in America. Aha.org. Published January 2022. Accessed May 9, 2023. https://www.aha.org/system/files/2018-04/value-initiative-icd-10-code-social-determinants-of-health.pdf Level of MDM (based on 2 of 3 elements of MDM) number and complexity of problems addressed. ACEP: American College of Emergency Physicians – Advancing Emergency Care. ERCODER. Acep.org. Accessed May 9, 2023. https://www.acep.org/siteassets/sites/acep/media/reimbursement/acep---2023-ed-mdm-grid.pdf Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!
This ad-free episode of Out of Patients is made possible by the Community Oncology Alliance (COA), a nonprofit organization dedicated to advocating for community oncology practices and, most importantly, the patients they serve. COA is the only organization dedicated solely to community oncology, where most Americans with cancer receive treatment. Learn more at https://timetoscreen.org.In today's episode, Matthew is joined by Debra Patt, M.D., Ph.D., MBA, a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics.Their conversation ranges from cancer screenings, medical burnout, and COVID's impact on society to physician self-care, rural health challenges, and the mandatory dosage of 80s pop culture references.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Discussing AACR 2023 Highlights - focusing on 3 studies that potentially could impact our practice in the community from this conference. - AEGEAN study for Non-Small Cell Lung Cancer - Keynote 966 for Cholangiocarcinoma - SWOG S1512 for Desmoplastic Melanoma
In this episode, we discuss community oncology and social media's role in sharing knowledge. The OncBrothers, Dr. Rahul and Dr. Rohit Gosain, share their experiences working in the field and using social media to connect with colleagues. They emphasize the importance of better access to genomic testing and targeted therapies and the need for patients to ask their oncologists about these options.
The success of an effective clinical research program is essential for developing and maintaining a top-tier clinical research trial team. Join our next podcast on clinical trial management as Dr. Robert Neff interviews Dr. Bradley Monk, Dr. Mark Shahin, and Ashley Douglas, RN, BSN, OCN addressing clinical trials from a community oncology perspective. The discussion includes building a quality clinical trial team, relationship development with industry partners, cooperative group involvement (NRG), the process for initiating clinical research at home institution, and important pitfalls to avoid as a new researcher among other topics. This episode was moderated by Robert Neff, MD, a member of the SGO Education Committee's Clinical Trials Management/Concepts Subcommittee. Special thanks to Bradley Monk, MD, Mark Shahin, MD, and Ashley Douglas, RN, BSN, OCN for your contribution to this episode.Sound engineered and produced by Betheon Whyte on behalf of the Society of Gynecologic Oncology.
In the second of a three-part series on “changing the culture of oncology,” Dr. Sanjay Juneja shares three technologies he's excited about and why—technology that detects circulating tumor DNA to reveal if cancer is present, technology that facilitates real-time testing of a specific treatment on a patient's tumor cells before initiation of the anti-cancer regimen, and more. Guest: Sanjay Juneja, MD Chief of Oncology Service Baton Rouge Medical Center Baton Rouge, LA Board Member of the Louisiana Oncology Society “Always lean on what you know. And we know the immune system has protected all of us. If you are listening to this, you have beat cancer. And your immune system did it for you.” Resources: 2022-2023 President's Theme: Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience Data Analytics + Business Intelligence = Operations Insights ACCC Forum Focuses on Technology Solutions to Mitigate Workforce Shortages Cardinal Health: The Value of Clinical AI in Community Oncology
While remote monitoring platforms have been used effectively throughout the COVID-19 pandemic to reduce the burden on patients and healthcare facilities around the country, Vanderbilt Ingram Cancer Center in Nashville, Tenn., has been using the technology in a different capacity—with its patients on CAR T-cell therapy. To avoid a lengthy inpatient stay, these patients are seen daily in Vanderbilt's outpatient clinic and then monitored virtually 24/7 at home or—for those who must travel to receive treatment—at their temporary lodging. The remote technology alerts cancer program staff of any significant changes in clinical status that would initiate a hospital admission. Guest: Brittney M. Baer, BSN, RNPatient Care CoordinatorVanderbilt University Medical Center Resources: Bringing CAR T-cell Therapy to Community Oncology Overview CAR T-cell Practice Profile – Fox Chase Cancer Center CAR T-cell Practice Profile – Billings Clinic Cancer Center Gap Analysis: Bringing CAR T-cell Therapy to Community Oncology IO Insight: Telemedicine and Cancer Care
Worta McCaskill-Stevens, the National Cancer Institute's director of the Community Oncology and Research Program and Joan Lunden, journalist and advocate, join Washington Post Live to discuss long-standing health disparities, new approaches to treatment and providing holistic care to patients beyond medicine.
Season 3 Episode 10- Wayne Woodbury- Community Oncology and Community Service On today's episode of The PQI Podcast we welcome Wayne Woodbury, BSPharm, R.Ph Mr. Woodbury is the Pharmacy Director at Southern Oncology Specialists, a Medical Oncology/Hematology practice with five locations in the Greater Charlotte, North Carolina area. He has overseen the growth of the practice's medically integrated pharmacy by broadening new to market product offerings, expanding payer relations, and improving medication therapy management and patient outcomes by adhering to accreditation performance standards. A graduate of Massachusetts College of Pharmacy and Health Sciences in Boston, MA, he has over 20 years of service in the fields of community, retail, long-term care, oncology/hematology and specialty pharmacy. He is a certified immunizer with experience in pharmacy management, legal and regulatory adherence, drug compounding, medication therapy management, and patient care. He currently sits on the Advisory Board for WeINSPIRE (www.weinspiremovement.org ), a multimedia platform that connects people doing good, generates inspirational stories, and ignites positive action. Through Ambassadors, internships, and stories WeINSPIRE seeks to ignite positivity and joy. Mr. Woodbury is also the Founder & Principal Clothier at Woodbury Collection, a clothing brand that focuses on concierge image curation. Woodbury Collection was founded in 2009 on the premise that every individual is the sum of their unique composition and experiences. The mission is to help individuals discover their personal style by pinpointing and accentuating that individuality. Today we discuss his path into oncology, the importance of community service and challenges he faces in Community Oncology.
Learning ObjectivesDiscuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC. Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care. Supported by independent educational grant from Gilead.Presented by Creative Educational Concepts, LLC.
Chadi's guest Kashyap Patel (@KashyappatelMd), MD, president of the Community Oncology Alliance (COA), joins the show to give an update on the current initiatives and state of COA and community oncology as a whole. He chronicles his journey to becoming a medical oncologist at a small community center outside of Charlotte (SC) and how he became aware of the pain points of community oncology in the U.S. The conversation moved into the history and initial aim of COA to help community practices prepare to work with and have an identity when facing policymakers, how COA membership dues are put to use, the top five problems facing community oncology today, and why many community practices feel compelled to sell to large health systems. Dr. Patel also shares his vision as the president of COA and what he hopes to accomplish before his term ends. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
Robin Shah is the Founder and CEO of Thyme Care, an oncology care management solution providing high-touch, tech-enabled cancer care navigation. Thyme Care was founded with the mission to radically improve the journey for every person diagnosed with cancer. At the heart of it all is the belief that providing patients with access to the right team at the right time will lead to better quality, outcomes, costs, and ultimately patient experience. Before launching Thyme Care, Robin was a founding member of OneOncology, where he served as the Chief Development and Marketing Officer. Robin's passion for building a stronger future for community oncology then brought him to Flatiron Health, a leading healthcare technology company. There, Robin served as Vice President of Provider Marketing and Strategy. Robin also helped manage a comprehensive community cancer center in his hometown, Gettysburg, PA. Robin earned his bachelor's degree in biomedical engineering from George Washington University and holds an M.B.A from the Carey Business School at Johns Hopkins University.John Marchica, CEO, Darwin Research GroupJohn Marchica is a veteran health care strategist and CEO of Darwin Research Group. He is leading ongoing, in-depth research initiatives on integrated health systems, accountable care organizations, and value-based care models. He is a faculty associate in the W.P. Carey School of Business and the graduate College of Health Solutions at Arizona State University.John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is an active member of the American College of Healthcare Executives and is pursuing certification as a Fellow.About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin's client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
Join us as Dr. Mackenzie walks us through his experiences in the field, where he sees us going, and the big changes on the horizon for his clinic!
Precision medicine is refocusing which clinical trials are possible, but we still have a ~5% participation rate and non-diverse patient demographic. Community oncology is the doorway to changing the face of clinical trials in the era of precision medicine. In this podcast, we talk about why, how and what's in it for your practice to facilitate clinical trials in the community setting.Learn more about our partners at VieCure.Dr. Paul Bunn Jr., MD, FASCO: Dr. Bunn is a Distinguished Professor, VieCure Clinical Advisory Council Member, and James Dudley Endowed Chair in Lung Cancer Research Division of Medical Oncology University of Colorado.Dr. Fred Ashbury, PhD, MACE: Dr. Ashbury is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure's oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of the treatment strategy rules that underpin our platform.The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.
This episode features Yuri Fesko MD, with clinical pathways to help guide diagnosis and treatment in oncology. In this session, Dr Fesko discusses: How clinical pathways can make an impact for hospitals to improve oncology outcomes The critical importance of collaboration for pathologists and oncologists The future of oncology care in integrated health systems Yuri Fesko MD Bio: Dr Yuri Fesko serves as the Executive Medical Director of Medical Affairs at Quest Diagnostics, and the Chief Clinical Officer for Oncology Strategic Collaboration at Quest. Born and raised in New York City, Dr Fesko trained at Case Western Reserve University, and completed his fellowship at University Hospitals of Cleveland. After his fellowship, Dr Fesko served as the Chief of Community Oncology for Wake County through Duke University Health System.An experienced oncologist and medical business leader, he is currently responsible for strategic clinical development at Quest across multiple functional areas including Regulatory FDA, HEOR, and R&D. ----more---- ------------------------------ Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
To learn more about payer preferences, click here.To see how Minnesota legislators are working to override payer preferences, click here.For more on payer influence on prescribing patterns, click here.For more on NCCN’s biosimilar work, click here. You can also check out part 1 and part 2 of this series.To check out our Biosimilar Approvals navigator, click here.
On today's episode meet Lee Schwartzberg, MD, FACP. Dr. Schwartzberg is a medical oncologist and the Medical Director of West Cancer Center. He is also the Chief Medical Officer at OneOncology, an organization that invests in and collaborates with practices to deliver comprehensive cancer care in communities. A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg served on the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. Today we are talking about bringing precision medicine to community oncology practices.
Dr. Kashyup Patel is CEO of Carolina Blood and Cancer Associates. As a Medical Oncologist, Dr. Patel has worked hard to institute care initiatives that foster ease of access for patients suffering from cancer while improving metrics that save time and money. He is a leader within his specialty and has fearlessly tested and implement alternate payment models. As a patient advocate, he has worked tirelessly to define and create "patient-centered care." His strategic thinking is notable, and this year he takes the helm as President of the Community Oncology Alliance. We discuss the challenges unique to patients diagnosed with cancer in the community setting in addition to the difficulties facing so many clinicians today. Dr. Patel is placing an emphasis on addressing ethnic and racial disparities in cancer care - from diagnostics and precision medicine to enrollment in clinical trials. His interests run deep and range from healthcare policy, value-based initiatives, to advocating for the adoption of biosimilars and more. He is a person that is deeply fond of his patients and his warm, kind personality is felt throughout our conversation - all the more reason to champion his cause. In this intimate dialogue, we also discuss his recent book “Between Life and Death: From Despair to Hope,” which chronicles real patients facing end-of-life concerns with compassion, acceptance, and understanding. He shares stories that bring peace and consolation for all of us who have suffered loss from cancer. We end on a note of optimism as Dr. Patel highlights his driving ambition in life which is that the glass is always full - even if it contains but a drop of water. To order "Between Life and Death: From Despair to Hope," click here.
Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how community oncology practices are recovering from the COVID-19 pandemic and keeping focused on the goal of providing value-based care. The webcast on which this podcast episode is based was originally presented on August 26, 2020. The replay can be accessed here: http://www.valuebasedcancer.com/avbcc/covid-19-webcast-series/webcast-replays/2703-august-26-2020-the-road-to-recovery-for-community-oncology-practices-covid-19-recovery-the-road-ahead.
Guest host Dr. Miriam Knoll, radiation oncologist at the John Theurer Cancer Center at Hackensack Meridian Health, interviews oncologists about the decisions and extraordinary moments that have shaped their careers in this special podcast series. In this episode, Dr. Knoll speaks with Dr. Suzanne Cole, director at University Hospital Simmons Cancer Clinic at UT Southwestern Medical Center, about her early-career leap of faith to move from academia to a remote community oncology practice. TRANSCRIPT: Dr. Miriam Knoll: Welcome to the ASCO Daily News Podcast. I'm Dr. Miriam Knoll and I'm delighted to be the Daily News guest host for a special podcast series that explores a full spectrum of oncology careers. I am an early career radiation oncologist. And in this series, I'll bring you interviews with a wide range of oncologists to hear about their diverse experiences, greatest challenges, and the unforgettable moments that shaped their careers. Dr. Miriam Knoll: In today's episode, I'm thrilled to welcome Dr. Suzanne Cole, a medical oncologist at UT Southwestern Medical Center. She serves as a director of the University Hospital Simmons Cancer Clinic at the UT Southwestern Medical Center at Richardson/Plano. Dr. Cole and myself report no conflicts of interest relevant to this podcast. Full disclosures relating to all Daily News Podcast can be found on our episode pages. Dr. Cole, welcome to the podcast. Dr. Suzanne Cole: Thank you so much for inviting me. Dr. Miriam Knoll: So I'm so excited to have you here. You and I met on social media, which is becoming way more common nowadays. Would you agree? Dr. Suzanne Cole: I totally agree. Dr. Miriam Knoll: So I'm going to ask you about the HEME/ONC women's Facebook group a little bit later. But right now I first wanted to ask you about your career trajectory. Because I know that you first started off after you completed your training working in the community and more recently joined UT Southwestern. Dr. Suzanne Cole: That's true. Dr. Miriam Knoll: How did that come about for you? Dr. Suzanne Cole: So I think that my story is not unlike other women who may be considering, you know, various options coming out of fellowship as far as what do they want to do or where do they see themselves. But I think I also had some kind of just normal life family pressures that pushed me in a certain direction. So I did my fellowship at MD Anderson. Dr. Suzanne Cole: And when I went there, I thought I might be a stem cell transplant doctor. And I spent my first year in clinic kind of embedded in a transplant clinic and doing a lot of inpatient. And, you know, I kind of learned during that time that transplant probably wasn't the right fit for me. And I really didn't love any particular other tumor type enough to kind of then switch gears and dedicate my life to like one specific type of cancer. Dr. Suzanne Cole: And so I told my program that I thought I was probably going to end up being a generalist and go back into the community. Most of my family is in Dallas. And that's where I was kind of hoping to land eventually. And I focused the last couple years of my fellowship on just really getting a very broad education in all of the tumor types. Dr. Suzanne Cole: And then also, I think that this is important for women and men, but I'm the breadwinner of my family. I have four children. My husband is a musician. And when I was coming out of fellowship, I was probably about $250,000 in debt. And my oldest son was kind of getting close to needing to go to college. Dr. Suzanne Cole: And, of course, like, I'd been in training and med school and residency for most of his growing up. And I had nothing set aside for his college. So I really needed to be in a place where I could be in a situation where I could pay off my loans and also save money for college. And, to be quite frank, a lot of the entry level academic positions just would not allow me to financially get my loans out of the way and also prepare for college, which was coming in a very short period of time for my oldest son. Dr. Suzanne Cole: So I ended up taking a job in Charleston, West Virginia, where I was able to kind of get a loan payment situation taken care of. And I worked in this underserved area and was able to, basically, get financially straightened out within the first four years of my career. And it was a really fantastic place to cut my teeth as an oncologist. Dr. Suzanne Cole: Because I was working for a very large hospital system called CAMC. And they have this network of hospitals in Charleston that basically serves the entire southern half of West Virginia. It's a huge patient population that filters into this kind of safety net hospital. Dr. Suzanne Cole: And when I joined that practice, I was one of nine oncologists. So I had a lot of great partners to just help me and mentor me. But we took care of anything that walks through the door from acute leukemia to rare sarcomas to bread and butter breast cancer, prostate cancer, colon cancer. And also benign hematology, we had the hemophilia center for the state. And it was a really fascinating, busy, very robust and varied type of first practice. Dr. Suzanne Cole: And I also was very fortunate that they had a pretty well-developed community oncology research program. And I was able to put patients on clinical trial, which was very gratifying. Because coming out of fellowship at MD Anderson, everybody was on trial. And I was very comfortable with having that access to research and giving options to patients that was beyond the standard of care. And so that was my first four years in practice. Dr. Miriam Knoll: Wow, so can you tell us more, you know, logistically, you mentioned that you were looking for a certain type of, you know, let's say loan repayment or job security and compensation and that you were comparing your opportunities. You know, did you, you know, work with a recruiter or did people reach out to you? You know, what was that process like for you? Dr. Miriam Knoll: Because I think a lot of our listeners would be interested in hearing more about, you know, how does one look for different types of job opportunities if they're considering more than one type of practice? And I think that's something that a lot of people don't really admit when they're looking for a job. Because a lot of people say, "Oh, I'm only looking for academics" or "I'm only looking for private practice." And, you know, that isn't the case for all of us. Dr. Suzanne Cole: Yeah, and I'll tell you, I felt like pretty on my own because I was in an incredibly academic environment. I was kind of the only fellow that I was aware of at that time that was saying, "I'm planning on going back into the community and not into academia." And so, you know, everyone around me as far as faculty members like really couldn't mentor me or help me navigate how to do that well. Dr. Suzanne Cole: And so in my second year of fellowship, I actually started looking for jobs at that time. And my husband and I were kind of looking possibly to go back to Dallas. But at that time, this was in like the 2008 economic crash that was going on. And because I had done my residency at UT Southwestern, I had a lot of friends who were in practice in Dallas and in that community. And the jobs were just drying up. Dr. Suzanne Cole: Like a lot of the private practice or community oncology programs were just not sure financially what was happening nationally. And so they weren't putting out new jobs because they weren't sure that they would be able to support bringing on another partner. And so when I realized that the Dallas market was not looking like a feasible option, I kind of thought, "Well, look, you know, I don't really have any ties to anywhere else. I'm going to cast a very wide net and I'll look, you know, from California to Maine and just see what's the best opportunity for me to get my loans taken care of and to get into a good group where I have like a feeling of mentorship from colleagues and a good vibe from the team." Dr. Suzanne Cole: And I started looking at just kind of all kinds of random opportunities across the United States. And, you know, to be quite honest, when the West Virginia job came onto my radar, I thought, "Mm, you know, it's West Virginia. I don't have any connection to that place. You know, I'm not sure that this is going to be, like, Option A, B, C, or E, but it might be Option F." Dr. Suzanne Cole: And then I went out to interview and I just, I really loved the people. I was actually quite impressed by the scale of their operation. I had trained at Parkland in Dallas for my residency. And so I was used to this kind of hospital system that was caring for underserved populations. Dr. Suzanne Cole: And what I found very attractive about it was that in that hospital system, if you needed a cardiothoracic surgeon, if you needed interventional radiology, if you needed a GI endoscopist who could do stents or interventional things, those things were all in place. And so it was kind of the size of the system that was attractive to me, but then also the partners that I interviewed that lured me to kind of think about that job. And then I went for a second interview. Dr. Suzanne Cole: And it came to the top of the list just because of the whole package. But it was a real leap of faith to pack up my family and move across the country by ourselves to, you know, a very remote part of the country where we didn't have a lot of support either from friends or family. And we were just kind of loners showing up in this city together. Dr. Suzanne Cole: But it worked out. And it was I think it was one of the best decisions that I've ever made because I was able to like become very independent as a practitioner and really feel confident that I could handle anything that came through the door. And then it also just kind of launched my research career in community practice, which is not something that's easy to find or carve out for yourself. And so I just felt like it was a very fortuitous way everything came together. Dr. Miriam Knoll: Can you tell us about your transition to UT Southwestern? Dr. Suzanne Cole: So there was a little bit of a break in the middle of that. As my younger children were approaching elementary school, we started looking to try and get closer to Texas where both my husband and my family are in Texas. And so about four years after I had been in West Virginia, we started looking back in Dallas again. Dr. Suzanne Cole: And, again, kind of the job market was still not where I was-- there was nothing there that was kind of interesting to me as far as having the clinical research component, but also general community practice. And so I kind of widened my scope again and found a job in Oklahoma City at Mercy Hospital where they also have this very robust community practice, I had multiple partners, and a very strong community-based clinical research program. And Oklahoma City is about three hours from Dallas. Dr. Suzanne Cole: And so it was not that far from my family. So we decided to take that position. And we settled in Oklahoma and stayed there for four years. And I thought I would probably never leave. I was, you know, very happy. My job was really good. Dr. Suzanne Cole: And then I got this flyer in the mail. It was like a super random thing where I get home from work one day and I'm kind of going through the junk mail. And there is this flier advertising UT Southwestern Community Oncology Practice in North Dallas, have access to over 300 clinical trials, you know, be connected to the university, but be embedded in your community. Dr. Suzanne Cole: And, you know, I have like this huge allegiance and great love and respect for you UT Southwestern, which is where I did my medical school and residency. And it's a job in Dallas that is kind of-- if I could dream up on paper exactly what I would see myself doing for the rest of my life in a kind of hybrid setting, that was kind of what was on this flyer. And I told my husband, I was like, "I'm just going to like send them my CV and see what happens. I'm sure nothing will come of it." Dr. Suzanne Cole: But they called me the next day. And I came to interview like maybe a week or two later. And it was just this kind of perfect fit. Because they really needed somebody who could do all of the cancers, benign hematology, you know, would be able to see anything that walks through the door in the community. But they also were looking for somebody that had kind of an academic mind as far as thinking about how to get clinical trials available to the patients, collaborating with the main campus, being part of tumor boards and presenting patients, and, you know, kind of leveraging the strengths of a University within the community practice. And I think like if I had written down my dream job, every kind of point that I wanted, you know, on paper, that is what has come to pass in the last year and a half that I've been here. Dr. Miriam Knoll: Wow, that's really an amazing story. And thanks so much for sharing it with us. Dr. Cole, I wanted to ask you about your story about founding the hematology and oncology women's Facebook group, renamed the HEME/ONC Wolf Pack group after Abby Wambach's Barnard commencement address in 2018. So, of course, I'm a member of the group. And can you tell us, what were you thinking when you started the group? And were you thinking about it from a social perspective, from a career perspective? And what would you tell other oncologists who are thinking about potentially getting involved in social media? Dr. Suzanne Cole: So I think that the social media stuff happened to me by accident. I mean, I was kind of like a partaker of social media. I used Facebook to stay in touch with family and friends. And I would say it was probably five years ago now that-- it might have been six-- the physician mother's group came about. And I don't know why, but for some reason I got added to that group when it was very young and very small. Dr. Suzanne Cole: And I remember kind of seeing posts on the physician mother's group, which is now-- I don't how many people are on it. But it's probably close to 100,000 women physicians across the world. When I was first part of that, it was maybe 5,000 people were on the site. And I remember seeing a colleague of mine in Oklahoma City, who was an ER doctor, make a comment that, you know, on the physician mothers group ER subgroup, they had discussed this issue about emergency medicine. Dr. Suzanne Cole: And I thought, wow, is there like a HEME/ONC group that I could join? Because I would love to talk with other women about issues that are specific to hematology and oncology. And the response that I got from the masses was that, you know, nobody was aware that there was any kind of physician mothers' group that had a HEME/ONC subset. And so I just decided to start one that day. Dr. Suzanne Cole: And when I reached out to Hala who runs PMG she said, you know, we don't sanction any official physician mother group subgroups. And so if you want to make a HEME/ONC group, that's fine. But it'll be kind of separate from the PMG platform. Dr. Suzanne Cole: And so I just basically went through my friend list and added every woman physician that I could think of that was on Facebook with me. And we probably started with like 25 people. And it has grown into this really amazing network, support, resource. You know, I'd say that the thing that people use it the most for is for advice on de-identified cases. Dr. Suzanne Cole: You know, somebody posts a case about, "I have a lady with breast cancer and she's been through these three lines of therapy and, you know, she's progressing in this way, what would you say would be the next step?" And what I also find very cool about our group is that we have multiple experts in particular fields who will kind of weigh in and point out clinical trials that may be available or say, you know, in that situation, I would kind of reach for this drug next. And it's been also just very supportive from, like, a human being perspective. Dr. Suzanne Cole: Just because, you know, we have patients that are critically ill. And we're constantly dealing with sad things happening to patients that we really care about. And it's become a little bit of a safe space for physicians to kind of say, "Hey, you know, one of my favorite patients died and today and I'm just feeling really torn up about that" and get a whole lot of support from people all across the world that identify with that. And just you don't have to explain it. Everybody understands where you're coming from. Dr. Miriam Knoll: Yeah, I've personally seen both those things firsthand and been a beneficiary of that. So and I think there is even more support that people can find, both in terms of job opportunities, job advice, you know, how to set up your clinic, you know, the electronic medical record, negotiating salary, right? Have you seen posts like that too? Dr. Suzanne Cole: I feel like very recently there was a post about a woman who found out that her junior colleague was being paid, like, twice as much as she was. He was taking less call. You know, he had constructed his contract in a way that was very beneficial to him. Dr. Suzanne Cole: And when she brought it to the attention of her employers, they kind of were like, "So, you know, what are you going to do about it?" And by her just kind of putting that situation out there to us, she got so much feedback from the group about like, "This is not acceptable. You know, there are all these other opportunities. You can be paid fairly. You can be valued." Dr. Suzanne Cole: And within, I want to say, like two months, she had a different job. You know, she was like, "I don't have to put up with this because I'm not alone." and it was really cool to see that happen for somebody. Dr. Miriam Knoll: That rallying around, right? Dr. Suzanne Cole: Yeah, yeah. Dr. Miriam Knoll: Even though it's virtual. Dr. Suzanne Cole: It's virtual, but it's real, you know? And it's I think also the networking that goes on. Like I just, I know so many people who have given talks at different institutions who have had opportunities, you know, just kind of presented on our Facebook group. And they've snatched up the opportunity to be part of that. And it has helped them grow their network and their academic credentials. There's just a lot of things that could happen out of this if you are engaged and you take advantage of it. Dr. Miriam Knoll: So how can somebody join the group if they're not in it yet? Dr. Suzanne Cole: So because we are a private group, you have to know somebody who's already a member. And they need to kind nominate you to join the group. And then we verify that you are a physician in some type of hematology, oncology field. And we take HEME/ONC doctors, palliative care, surgeons, there's some dermatologists that specialize in skin cancers. Dr. Suzanne Cole: And so anybody who takes care of cancer patients or does hematology is welcome to join. And the requirements are, you have to be a physician, you have to be a woman. And we vet everybody to make sure that they are who they say they are. And then they are added in. Dr. Miriam Knoll: And radiation oncologists, right? Dr. Suzanne Cole: Oh, yes, radiation, definitely. Dr. Miriam Knoll: Don't forget about us. And actually now there is a separate radiation oncology women's Facebook group too. So if any listeners want to join that group, that's actually a group that grew out of the HEME/ONC group. Dr. Suzanne Cole: Yes, and there's also a pediatric hematology oncology subgroup that has kind of split off. And we still have all of those members as part of the bigger group, but I love that there's an opportunity for people to network with each other and discuss things that are particular to their subspecialties. Dr. Miriam Knoll: So what's the worst career advice you've ever gotten? Dr. Suzanne Cole: I think the worst career advice is to do what your-- what everyone around you is doing. I think there's like an incredible pressure when you're in training to conform to what is expected and to sometimes ignore those inner voices that are telling you, you know, "Hey, maybe this is not the right fit for me." I personally have always really struggled with writing. Like I don't enjoy it. Dr. Suzanne Cole: I love clinical medicine. I love seeing patients. I love participating in clinical trials. But I don't totally love writing them. So I think being browbeaten into pushing down a pathway that doesn't feel inspiring to you could be very, very detrimental to your long-term career. Dr. Miriam Knoll: What's the best career advice you've gotten? Dr. Suzanne Cole: So the best career advice I've gotten is know yourself and even if you're scared, go for it if you are excited and feel a passionate interest in something that may be a little off the beaten path. Dr. Miriam Knoll: And last question for you this morning, what advice would you give to trainees and early career oncologists? Dr. Suzanne Cole: So I would say really take time during your training and in the first one to two years that you're out of training to figure out who you are as a physician and what makes you happy. Because if you can find something that is setting you on fire, you're so passionate about this particular thing, it can carry you through the harder stuff that we all have to deal with throughout our careers. Dr. Suzanne Cole: So also to seek out different options. If you have, you know, an interest in community practice but you're not really exposed to it as is usual in a fellowship-type program, network and connect and try to speak with other people who are practicing in a place that you think, "I might be happy in this place." And you really need to talk to people who are doing it. Dr. Miriam Knoll: Dr. Cole, thank you so much for joining me this morning and for this amazing discussion. And thank you to our listeners for joining us for this episode of the ASCO Daily News Podcast. We'd love to have your feedback so please drop us a note at dailynews@asco.org. And rate and review us on Apple Podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Welcome to Alberta Health Services’ COVID-19 podcast. In this episode, Dr. Dean Ruether, AHS Medical Director for Community Oncology answer question about the impact the COVID-19 pandemic is having on Albertans living with cancer, including those going through treatment.
Outcomes for patients with cancer are continuously improving, but the increasingly complex healthcare system, new payment and delivery models that place more risk on practices, and rising costs of therapies has made it difficult for independent oncology practices to thrive and survive. However, independent practices present an important part of cancer care, delivering care to patients who are not near large hospital-based systems at lower costs. Sibel Blau, MD, explains how Quality Cancer Care Alliance is bringing together independent practices and helping them succeed by providing them with best business models, practice efficiencies, and financial advantages. Read more about the stories in this podcast: Data and Collaboration Are Key for Value-Based Care Success: https://www.ajmc.com/journals/evidence-based-oncology/2018/december-2018/data-and-collaboration-are-key-for-valuebased-care-success Strategies for Fighting Consolidation in Community Oncology: https://www.ajmc.com/conferences/coa-2019/strategies-for-fighting-consolidation-in-community-oncology Dr Ray Page Details Using Triage Pathways and Scaling Them Across Multiple Practices: https://www.ajmc.com/interviews/dr-ray-page-details-using-triage-pathways-and-scaling-them-across-multiple-practices Barry Russo on How Community Oncology Practices Can Work Together and Learn From Each Other: https://www.ajmc.com/interviews/barry-russo-on-how-community-oncology-practices-can-work-together-and-learn-from-each-other
The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care stories included encouraging results from the Next Generation Accountable Care Organization model; concerns that CMS' new billing rules will hurt the sickest patients; a study confirms the value of daily aspirin for patients with diabetes. Read more about the stories in this podcast: Next Generation ACO Model Saves $62 Million in First Year: https://www.ajmc.com/focus-of-the-week/next-generation-aco-model-saves-62-million-in-first-year Patient, Provider Groups Tell CMS Proposed E/M Service Cuts Will Hurt Sickest Patients: https://www.ajmc.com/newsroom/patient-provider-groups-tell-cms-proposed-em-service-cuts-will-hurt-sickest-patients ASCEND Results Confirm Aspirin Prevents Primary Vascular Events in Diabetes: https://www.ajmc.com/focus-of-the-week/ascend-results-confirm-aspirin-prevents-primary-vascular-events-in-diabetes- Senate Moves Forward With Drug Price Transparency Amendment: https://www.ajmc.com/focus-of-the-week/senate-moves-forward-with-drug-price-transparency-amendment The Financial Impact of the Sequester Cut to Medicare Part B Drug Reimbursement in Community Oncology: https://www.ajmc.com/contributor/coa/2018/08/the-financial-impact-of-the-sequester-cut-to-medicare-part-b-drug-reimbursement-in-community-oncology
Scott Weissman, founder of Chicago Genetic Consultants, discussing being an entrepreneur and genetic counselor at his private practice along with the subfields of genetic counseling he focuses on including cardiogenetics, hereditary cancer, and carrier screening. He shares his expertise on direct-to-consumer genetic testing offered from a variety of companies. Scott Weissman is a trailblazing genetic counselor who recently started his own independent practice, Chicago Genetic Consultants. He has previously been a genetic counselor at GeneDX and NorthShore University HealthSystem. Scott has received the Strategic Leader Award from the National Society of Genetic Counselors for working on multiple projects related to Medicare guidelines for cancer genetic testing, publishing genetic counseling and testing vignettes in the journal Community Oncology, and the United States Preventative Services Task Force BRCA genetic counseling guidelines. Scott is currently a Clinical Faculty member at the Northwestern University Graduate Program in Genetic Counseling and a senior genetic counselor at Aurora Health Care.
On the Wednesday, January 19th 2011 program at 11AM Pacific and 2PM Eastern, my guest commentator is thought leader, nationally known blogger, health care analyst, business development consultant, writer and speaker on health care cost and quality issues Brian Klepper, Ph.D. For more information, see: http://careandcost.com/ Over many years, Brian Klepper has developed a national reputation for thoughtful, reasonable perspectives on complex health care issues. Dr. Klepper consults with health care organizations and business groups to create market visibility that leverages performance, and to take advantage of emerging trends that promise to positively transform both health care quality and cost. Dr. Klepper serves as Editor for MedPedia, as Editor-at-Large for Community Oncology, and as one of only three non-physicians on the International Editorial Board of Medscape General Medicine, and is also a regular columnist on several of the best-respected and most widely-read expert health care blogs - The Health Care Blog, Health Care Policy and Marketplace Review, Health Commentary and Health Wonk Review. Klepper is a Principal in three firms. Healthcare Performance provides market analyses and strategic services to the industry. Health 2.0 Advisors counsels health care firms on ways to use the Web to facilitate knowledge exchange, patient engagement, pricing and performance transparency, transactional streamlining and decision support. WeCare TLC develops and manages onsite clinics for employers and other organizations. Please join us for an informative exchange!
© 2020-2025 Ivy Podcast Discovery LLC
